MANILA, Philippines — The Department of Science and Technology (DOST) is set to start the clinical trial for mix and match COVID-19 vaccines.
The trial will be conducted in the cities of Manila, Marikina, Muntinlupa, Dasmarinas, and Davao.
The DOST said it is awaiting the final approval of the Food and Drug Administration (FDA) to conduct the trial.
DOST Undersecretary for Research and Development Rowena Guevara said the agency is currently holding training and virtual site initiation visits in areas where the clinical study will take place.
“Sa kasalukuyan, hindi pa tayo nagre-recruit dahil inaantay namin ang final approval ng FDA bago tayo magsimula ng pagbabakuna. Ngunit ang project team ay handa na po,” Guevara said.
The DOST are looking for unvaccinated individuals aged 18 and above to participate in the trial.
Pregnant women and those who have contracted the disease can no longer join the study.
Those with comorbidities may join the trial as long as they are able to seek clearance from the doctors that they are medically stable.
The participants in the trial will be divided into three groups with the first group to be vaccinated with Sinovac vaccines for the first and second dose.
The second group will be injected with Sinovac for the first dose and other brands such as Pfizer-BioNTech, Moderna, AstraZeneca, or Sputnik V for the second dose.
The third dose, on the other hand, will receive Sinovac for their first and second dose, and another brand as a booster shot.
“Iyong isang grupo na pag-aaral ay bibigyan ng Sinovac at Sinovac lang. Tapos iyong pangalawang grupo naman, marami sila bibigyan ng Sinovac bilang first dose, tapos 250 bibigyan ng Pfizer-Biontech, Moderna, AztraZeneca, o Sputnik V bilang second dose. Iyong pangatlong grupo naman ang mayroon third dose o booster. Sinvoac ang ibibigay na una at second dose tapos Pfizer, Moderna, AstraZeneca o Sputnik V ang gagamitin na third dose,” Guevara said. —/mbmf (from the report of UNTV Correspondent Aileen Cerrudo)